| Name | LX-2761 |
|---|---|
| Synonyms |
N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-((2S,3R,4R,5S,6R)-3
LX2761; LX-2761; LX 2761;1610-6 N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide N-(1-((2-(Dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-(3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran -2-yl)benzyl)phenyl)butanamide Benzenebutanamide, N-[2-[[2-(dimethylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-4-[[2-methyl-5-[(5R)-5-C-(methylthio)-β-D-xylopyranosyl]phenyl]methyl] LX-2761,LX2761 |
| Description | LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2.2 nM (hSGLT1), 2.7nM (hSGLT2)[1] |
| References |
| Molecular Formula | C32H47N3O6S |
|---|---|
| Molecular Weight | 601.31 |